Observational studyBiomolecules & biomedicine2026
Advanced glycation end product accumulation and AGEs-RAGE axis biomarkers in plasma and synovial fluid are associated with osteoarthritis severity.
Observational study in Biomolecules & biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a common whole-joint degenerative disease characterized by cartilage degradation, subchondral bone remodeling, synovial inflammation, and incompletely understood molecular mechanisms. Advanced glycation end products (AGEs) may contribute to OA pathophysiology by altering extracellular matrix properties and activating inflammatory signaling through the receptor for advanced glycation end products (RAGE). This study investigated the association between AGE accumulation and OA severity and evaluated AGE-related biomarkers in plasma and synovial fluid. In this cross-sectional observational study with prospective recruitment and retrospective clinical and radiographic assessment, skin AGE accumulation was measured by skin autofluorescence (SAF) in 404 outpatients aged 55-75 years. Lower-limb OA burden was assessed using clinical and available radiographic data for hip and knee OA, while hand osteoarthritis (HOA) was evaluated clinically. In a surgical subgroup of 42 participants, plasma AGEs, assessed as Nε-(carboxymethyl)lysine (CML), and soluble RAGE (sRAGE) concentrations were measured using enzyme-linked immunosorbent assay (ELISA). Paired plasma and synovial fluid analyses were performed in 21 OA patients with available synovial fluid samples. Higher SAF was independently associated with greater lower-limb OA severity after adjustment for age, sex, body mass index (BMI), and smoking status [odds ratio (OR) 4.06, 95% confidence interval (CI) 2.54-6.46; p < 0.001]. SAF was also strongly associated with HOA (OR 15.0, 95% CI 7.29-30.91; p < 0.001). In the biochemical subgroup, SAF inversely correlated with synovial sRAGE (ρ = -0.571; p = 0.007), and plasma AGEs inversely correlated with plasma sRAGE (ρ = -0.481; p = 0.027). Both AGEs and sRAGE concentrations were lower in synovial fluid than in plasma. These findings support an association between systemic AGE accumulation and OA burden and suggest that altered AGEs-RAGE axis activity may contribute to OA pathophysiology. Further longitudinal studies are needed to clarify whether SAF may serve as a non-invasive biomarker of OA burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.